TP53 and ovarian adenocarcinoma: The effects were demonstrated across a cohort of TP53-mutated OC-PDXs derived from HGS ovarian adenocarcinoma [HGSOC (23), the subtype with the highest death rate (29, 30)], differing in their innate responsiveness to platinum.